Pharmacist Use of a Population Management Dashboard for Safe Anticoagulant Prescribing: Evaluation of a Nationwide Implementation Effort.

anticoagulation atrial fibrillation drug use review population health management venous thromboembolism

Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
09 Sep 2024
Historique:
medline: 9 9 2024
pubmed: 9 9 2024
entrez: 9 9 2024
Statut: aheadofprint

Résumé

Direct oral anticoagulants (DOACs) have complex dosing regimens and are often incorrectly prescribed. We evaluated a nationwide DOAC population management dashboard rollout whose purpose includes pharmacist review and correction of off-label dosing prescriptions. Using data from Veterans Health Affairs, we identified all patients prescribed DOACs for atrial fibrillation or venous thromboembolism between August 2015 and December 2019. Sites were grouped on the basis of the timing of moderate-high usage of the DOAC population management tool dashboard. Effectiveness was defined as the monthly rate of off-label DOAC prescribing and the rate of clinical adverse events (bleeding, composite of stroke or venous thromboembolism). Implementation was evaluated as the percentage of off-label DOAC prescriptions changed within 7 days. Among the 128 652 patients receiving DOAC therapy at 123 centers, between 6.9% and 8.6% had off-label DOAC prescriptions. Adoption of the DOAC population management tool dashboard before July 2018 was associated with a decline in off-label dosing prescriptions (8.7%-7.6%). Only 1 group demonstrated a significant reduction in monthly rates of bleeding following implementation. All sites experienced a reduction in the composite of venous thromboembolism or stroke following dashboard adoption. There was no difference in the implementation outcome of DOAC prescription change within 7 days in any of the adoption groups. Early adoption of the DOAC population management tool dashboard was associated with decreased rates of off-label DOAC dosing prescription and reduced bleeding. Following adoption of the DOAC population management tool dashboard, all sites experienced reductions in venous thromboembolism and stroke events.

Sections du résumé

BACKGROUND BACKGROUND
Direct oral anticoagulants (DOACs) have complex dosing regimens and are often incorrectly prescribed. We evaluated a nationwide DOAC population management dashboard rollout whose purpose includes pharmacist review and correction of off-label dosing prescriptions.
METHODS AND RESULTS RESULTS
Using data from Veterans Health Affairs, we identified all patients prescribed DOACs for atrial fibrillation or venous thromboembolism between August 2015 and December 2019. Sites were grouped on the basis of the timing of moderate-high usage of the DOAC population management tool dashboard. Effectiveness was defined as the monthly rate of off-label DOAC prescribing and the rate of clinical adverse events (bleeding, composite of stroke or venous thromboembolism). Implementation was evaluated as the percentage of off-label DOAC prescriptions changed within 7 days. Among the 128 652 patients receiving DOAC therapy at 123 centers, between 6.9% and 8.6% had off-label DOAC prescriptions. Adoption of the DOAC population management tool dashboard before July 2018 was associated with a decline in off-label dosing prescriptions (8.7%-7.6%). Only 1 group demonstrated a significant reduction in monthly rates of bleeding following implementation. All sites experienced a reduction in the composite of venous thromboembolism or stroke following dashboard adoption. There was no difference in the implementation outcome of DOAC prescription change within 7 days in any of the adoption groups.
CONCLUSIONS CONCLUSIONS
Early adoption of the DOAC population management tool dashboard was associated with decreased rates of off-label DOAC dosing prescription and reduced bleeding. Following adoption of the DOAC population management tool dashboard, all sites experienced reductions in venous thromboembolism and stroke events.

Identifiants

pubmed: 39248259
doi: 10.1161/JAHA.124.035859
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e035859

Auteurs

Geoffrey D Barnes (GD)

Frankel Cardiovascular Center University of Michigan Ann Arbor MI.
Center for Bioethics and Social Science in Medicine University of Michigan Ann Arbor MI.

Charity Chen (C)

Center for Clinical Management Research Ann Arbor Veterans Affairs Ann Arbor MI.

Rob Holleman (R)

Center for Clinical Management Research Ann Arbor Veterans Affairs Ann Arbor MI.

Joshua Errickson (J)

Center for Statistical Consultation and Research University of Michigan Ann Arbor MI.

F Jacob Seagull (FJ)

Center for Bioethics and Social Science in Medicine University of Michigan Ann Arbor MI.

Michael P Dorsch (MP)

Frankel Cardiovascular Center University of Michigan Ann Arbor MI.
College of Pharmacy University of Michigan Ann Arbor MI.

Arthur L Allen (AL)

Veterans Affairs Salt Lake City Health Care System Salt Lake City UT.

Patrick Spoutz (P)

Pharmacy Benefits Management Veterans Integrates Service Network 20 Vancouver WA.

Jeremy B Sussman (JB)

Center for Clinical Management Research Ann Arbor Veterans Affairs Ann Arbor MI.
Division of General Medicine University of Michigan Ann Arbor MI.

Classifications MeSH